UK approves new BC drug after Serena-6 Phase 111 Trial
Australia often follows other countries with BC trials & drug approvals .... let's hope this trial happens in Aussie, too. The Institute of Cancer Research, London, strongly welcomes the news that camizestrant, a powerful new drug for advanced breast cancer that can be used to treat emerging tumours, has been approved by the medicines regulator, the MHRA. The drug has been approved to be used in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the treatment of ER-positive, HER2-negative, locally advanced or metastatic breast cancer. The approval is based on results from the SERENA-6 Phase III trial - funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris – which were published in the New England Journal of Medicine. You can read more about it here: https://www.icr.ac.uk/about-us/icr-news/detail/icr-welcomes-mhra-approval-of-breast-cancer-drug-that-targets-tumours-before-they-have-a-chance-to-grow Details on current (and past) Breast Cancer Trials in Australia can be checked here: http://www.breastcancertrials.org.auGroundbreaking genomic test could spare millions of breast cancer patients chemotherapy
I wonder if there were any members ON the Optima Trial? The Optima trial, led by University College London, followed more than 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. It found that those with a low score on the ge https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy Karen Bonham was part of successful trial for genomic test that determines which women with breast cancer can safely avoid chemotherapy https://www.theguardian.com/society/2026/may/29/breast-cancer-chemotherapy-genomic-test-case-study
Share your views: Information and support needs of people following treatment of breast cancer
Hi everyone, Erana from BCNA here! I’d like to invite you to participate in a research study opportunity led by James Cook University. Please see details below. If you can't access the QR code you can also follow this link Qualtrics Survey | Qualtrics Experience Management. If you have any questions or concerns regarding this research, please contact the research lead Tracey Ahern at [email protected] This study has been approved by the James Cook University Australia Human Research Ethics Committee (#H9326).Share your views: Artistic tattooing of breast-cancer mastectomy scars
Hi everyone! Following up on my previous post, I’d like to invite you to participate in a PhD research study being conducted by Tina-Maree Newlan of Charles Sturt University on artistic tattooing of breast-cancer mastectomy scars. The study aims to investigate the experiences of women who have had breast cancer mastectomy surgery and their experiences with making choices and decisions to decoratively tattoo mastectomy scars and what do those experiences mean for them. This request has been reviewed and approved by BCNA, and the project has been approved by Charles Sturt University Human Research Ethics Committee (Protocol number H24311). You are eligible to participate in this research study if you: are a women aged 18 or over have had an early breast cancer diagnosis, breast cancer mastectomy surgery and completed, or are in the process of completing, professional decorative artistic tattooing of mastectomy scarring Would like to participate in an interview and are English speaking sufficient to participate in an interview What does the study involve? Eligible participants would take part in an initial 60-minute interview (via Zoom or face to face, depending on geographical location relative to the Gold Coast) and then a subsequent second 30-minute interview around two months later. How do I take part? If you are interested in participating in this study or have any questions, please contact the researcher, Tina-Maree Newlan at [email protected]
ER+ HER- | Optima Study
Hi everyone I've just had a very interesting meeting with my oncologist - first appointment post surgery. Fortunately, I'm not a candidate for chemo (utter relief) so we didn't discuss this in any detail, but as we were talking about whether I should get a genomic test done or not, he mentioned that there was a new study about to take place - the Optima Study. From what I gathered from him, it'll offer a Prosigna (I think) test as part of the trial, which would obviously be funded (perhaps 100% - not sure) by the study. I think it'll be for people who are about to have surgery or who have recently had surgery - not sure though. I don't know anything further than that, and I couldn't find anything on any Australian sites about it, but there is some info on UK sites as it looks like the trial is being done there as well. Hope this helps someone - and saves someone a few dollars! Also hope this is appropriate to post!
Acupuncture study at Chris O’Brien Lifehouse
For ex-patients who have been treated for breast cancer at Chris O’Brien Lifehouse in Sydney; they are recruiting people who completed the cancer treatment but still experience pain, fatigue , sleep disturbance and/or numbness / tingling to participate in an acupuncture study that will run for 6 weeks from mid August to September. Free of charge. At the Living Room (for info [email protected])SHINE (The Sleep Health in Breast Cancer Study)
Hi Members, BCNA's Policy & Advocacy Team recently shared the below study which may be of some interest to you: SHINE (The Sleep Health in Breast Cancer Study-Evaluating the impact on psychological wellbeing and medication adherence) Researchers at the University of Strathclyde Sleep Research Unit in Glasgow (UK) are running a study to better understand physical and emotional wellbeing amongst people diagnosed with breast cancer. More specifically, the study aims to: · learn about wellbeing of people diagnosed with breast cancer · identify potential side effects of cancer treatment · support the development of future interventions, for people diagnosed with breast cancer who need to take hormone therapy. This project has been approved by the Strathclyde University ethics board. Who can participate? You can participate in this study if you: · are aged 16 years or older · have ever been diagnosed with breast cancer · have internet access. What does the study involve? The study involves taking part in an anonymous online survey which takes between 10 to 15 minutes to complete. The survey includes: · demographic questions · questions about breast cancer diagnosis · type of treatment · aspects of physical and mental health, and · hormone therapy adherence (where appropriate) How do I take part? If you are interested in participating in this survey, please visit here. If you would like further information, please contact [email protected]. This survey closes on April 31, 2022. By completing this survey you are providing your consent (agreement) for the University of Strathclyde (UK) to collect and store your survey answers on Qualtrics overseas server (large computer).Sydney University is doing a study on Fear of Recurrence ....... check it out
The things that pop into my FB stream ..... Yesterday it was notification that Sydney Uni is doing a 'Fear of Recurrence' Study & is asking anyone with breast or Ovarian cancers to take part ...... and to 'pick the right answer' - Yes or No - as to whether the answer is correct or not - the word/question/answer is about us reading more into (or overthinking) words or statements or symptoms. https://sydney.au1.qualtrics.com/CP/File.php?F=F_0lJ5WV6FXMxCJls I did it last night and if getting the answers wrong means that I have a fear of recurrence - I reckon I'll be in the top 10%!! :( I must have 'passed' - as I get another set of questions next week!! COGNITIVE BIAS MODIFICATION (CBM) FOR FEAR OF CANCER RECURRENCE/PROGRESSION You are invited to take part in a research study looking at a novel intervention for fear of cancer recurrence or progression (FCR), known as Cognitive Bias Modification (CBM). FCR is natural and common amongst cancer survivors, and leads people living beyond cancer to interpret many situations in light of their experience (a potential threat of recurrence or progression). CBM is an intervention that is administered online and trains people not to interpret ambiguous situations in a threatening way. By doing so, people reduce their anxiety. CBM has been shown to be helpful in a range of populations including in people with anxiety and depression. However there is only one pilot study in people living beyond breast cancer. That study achieved promising results, and we aim to test CBM in a larger trial to see if CBM does reliably reduce FCR, and if the results extend to women with ovarian cancer. https://sydney.au1.qualtrics.com/jfe/form/SV_8HRDp6WSgjjXXpA?fbclid=IwAR2fB8uR9MnChFi0ZcaClfxA5w3HI_B0jN6ZVvcOCzVo6MhXIz6nVJ77yc8
